Endocrine Abstracts

M shows an antiproliferative effect. In vivo, M reduces TSH in type 2 diabetes mellitus (T2DM) and DTC aggressiveness in DTC with T2DM. The aim of the study was to evaluate in DTC diabetic (Gr1, n=30 under M 1500 mg/day) and non-diabetic without (Gr2, n=83) or under M (gr3, n=84; M 1000 mg/day) the adjuvant role of M. Clinical and laboratory examinations were performed up to 24 months. At baseline the DTC groups were similar for age, gender, tumor st...

In thyroid nodules with indeterminate cytology, presurgical evaluations for risk management comprise biochemical tests, ultrasonography (US), elastography-US (USE), contrast-enhanced US (CEUS) and mutation analysis. The cytology of 130 Thy 3 nodules was reviewed according to the BTA 2014 classification. Nodules were divided into Thy 3a and Thy 3f categories. Histology was available in 97 nodules. Malignancy was the final diagnosis in 19% of surgically treated nodules. No signi...

After thyroidectomy (Tx) and RAI therapy, patients with diffentiated thyroid cancer are treated with levo-thyroxine to suppress TSH levels. Whether hyperthyroxinemia causes osteoporosis is debated. The aim of this study was to evaluate bone mineral density (BMD) and the fracture risk assessment tool (FRAX) in DTC women. FRAX calculates the 10-year probability of hip fracture (HF) and major osteoporotic fracture (MOF) in subjects aged >40. 46 women with DTC diagnosed and tr...